Crinetics-Vertex deal clears US antitrust waiting period, other approvals in hand

PUBT · 2d ago
Crinetics-Vertex deal clears US antitrust waiting period, other approvals in hand
  • Vertex plans to acquire Crinetics Pharmaceuticals via a merger, leaving Crinetics as a wholly owned Vertex subsidiary.
  • US antitrust review period expired at 12:45 p.m. ET on Aug. 12, 2026.
  • Clearances in Austria and Germany were received; Australia clearance received, pending a waiting period set to end Aug. 27, 2026.
  • Deal still requires Crinetics shareholder approval at an Aug. 28, 2026 special meeting.
  • Closing expected in early September 2026 if shareholders approve.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crinetics Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-032951), on August 14, 2026, and is solely responsible for the information contained therein.